{"article_title": "Diabetic Macular Edema Drugs Compared", "article_keywords": ["ranibizumab", "macular", "edema", "drugs", "study", "diabetic", "results", "trial", "patients", "compared", "treatment", "aflibercept", "vision"], "article_url": "http://www.hcplive.com/medical-news/diabetic-macular-edema-drugs-compared", "article_text": "Diabetic Macular Edema Drugs Compared\n\nAflibercept (Eylea/Regeneron) did better in treating diabetic macular edema (DME) than a far cheaper alternative bevacizumab (Avastin/Genentech) in a subset of patients who started treatment when their vision was 20/50 or worse.The finding was made in a three-year National Institutes of Health-funded clinical tria in whichl researchers compared three drugs, aflibercept, bevacizumab and ranibizumab (Lucentis /Genentech)Gains after two years were about the same for aflibercept and ranibizumab, though at the one-year point, aflibercept had shown a clear advantage.In patients whose vision was better at the start of treatment (20/32 or 20/40) the three drugs were about equal in effectiveness.The trial was conducted by the Diabetic Retinopathy Clinical Research Network, funded by the NIH\u2019s National Eye Institute.In a news release describing the results, NEI\u2019s Paul Sieving, MD, PhD, said \u201ceye care providers and patients can have confidence in all three drugs.Based on Medicare allowable charges, the per-injection costs of each drug in the doses used in the study were only $60 for Avastin but $1,200 for Lucentis and $1,850 for Eylea.The trial involved 660 patients with DME and ws done in 89 sites across the US.The study results were published in Ophthalmology . The lead author of the study is John A. Wells, MD, a retinal specialist at the Palmetto Retina Center, Columbia, SC.", "article_metadata": {"description": "Overall, three drugs available to treat diabetic macular edema all did a good job, researchers found in a national clinical trial. One costs $60 per injection, the others cost over $1,200 and $1,850. But the most expensive one did best in a subset of patients.", "og": {"site_name": "MD Magazine", "description": "Overall, three drugs available to treat diabetic macular edema all did a good job, researchers found in a national clinical trial. One costs $60 per injection, the others cost over $1,200 and $1,850. But the most expensive one did best in a subset of patients.", "title": "Diabetic Macular Edema Drugs Compared", "url": "http://www.hcplive.com/medical-news/diabetic-macular-edema-drugs-compared", "image": "https://s3.amazonaws.com/hcplive/v1_media/_upload_image/_thumbnails/eyemachine.jpg", "type": "Article"}, "msapplication-TileColor": "#ffffff", "msapplication-TileImage": "https://s3.amazonaws.com/hcplive/v2_media/_core/favi/ms-icon-144x144.png", "keywords": "diabetes, ophthalmology", "theme-color": "#ffffff"}, "article_summary": "Wells, MD, a retinal specialist at the Palmetto Retina Center, Columbia, SC.\nThe lead author of the study is John A.\nDiabetic Macular Edema Drugs ComparedAflibercept (Eylea/Regeneron) did better in treating diabetic macular edema (DME) than a far cheaper alternative bevacizumab (Avastin/Genentech) in a subset of patients who started treatment when their vision was 20/50 or worse.The finding was made in a three-year National Institutes of Health-funded clinical tria in whichl researchers compared three drugs, aflibercept, bevacizumab and ranibizumab (Lucentis /Genentech)Gains after two years were about the same for aflibercept and ranibizumab, though at the one-year point, aflibercept had shown a clear advantage.In patients whose vision was better at the start of treatment (20/32 or 20/40) the three drugs were about equal in effectiveness.The trial was conducted by the Diabetic Retinopathy Clinical Research Network, funded by the NIH\u2019s National Eye Institute.In a news release describing the results, NEI\u2019s Paul Sieving, MD, PhD, said \u201ceye care providers and patients can have confidence in all three drugs.Based on Medicare allowable charges, the per-injection costs of each drug in the doses used in the study were only $60 for Avastin but $1,200 for Lucentis and $1,850 for Eylea.The trial involved 660 patients with DME and ws done in 89 sites across the US.The study results were published in Ophthalmology ."}